19th Jun 2017 17:18
Abzena plc
Annual Report and Accounts for the Year Ended 31 March 2017
Cambridge, UK, 19 June 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, announces that its Annual Report and Accounts for the year ended 31 March 2017 is now available on the "Investors" section of the Group's website at http://www.abzena.com/about/investor-information/results-presentations/.
Printed copies of the Annual Report and Accounts are available from the Company Secretary, Abzena plc, Babraham Research Campus, Babraham, Cambridge CB22 3AT, UK.
-Ends-
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903498
|
Numis (Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam
| +44 20 7260 1000 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners Melanie Toyne Sewell / Alex Shaw | +44 20 7457 2020 |
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
· Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
· Cell line development for the manufacture of recombinant proteins and antibodies;
· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
· Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
· GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
Related Shares:
Abzena